Oncoinvent ASA, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across a variety of peritoneal metastases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer.
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit on Monday, May 20, 2024 at 9:00 a.m. ET.
Dr Yun Wang, principal investigator in the RAD-18-001 study in ovarian cancer, will present at the Norwegian Radium Hospital and Memorial Sloan Kettering Meeting “Updates and Controversies in Gynecological Oncology”. In the lecture titled “Novel radiopharmaceutical for peritoneal recurrence in ovarian cancer”, safety data from the dose escalation cohort when all patients had completed at … Read more
CEO, Anders Månsson will present Oncoinvent at the Cantor Fitzgerald Frontiers Radiopharma Virtual Summit
Newly elected members of Board of Directors consist of internationally merited business and clinical leaders
Formation of Scientific and Clinical Advisory Board leverages expertise of renowned Oncoinvent founders to support pipeline advancement
Members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.
Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.